← Leaderboards
Peter A Calabresi
Johns Hopkins University
$20,846,075
Attributed
$22,099,449
Total exposure
17
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,099,449 · 17
By mechanism
R01$12,203,920 · 2
U01$6,325,171 · 1
R37$2,966,316 · 1
R21$438,413 · 1
P41$157,852 · 5
M01$7,777 · 7
Top collaborators
- Shiv Saidha2 shared
- Kathryn C. Fitzgerald1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Lori Chaffin Jordan$8,910,492
- Shruti Chaturvedi$1,745,723
- Shiv Saidha$644,545
- Sarah A Reading$3,376,418
- Douglas S Kerr$15,455
Others in their field
Top investigators on “Multiple Sclerosis”
- David A. Hafler · Brigham And Women'S Hospital$33,720,341
- Vijay K Kuchroo · Brigham And Women'S Hospital$32,935,587
- Stephen L Hauser · University Of California San Francisco$32,469,388
- Katerina Akassoglou · University Of California San Diego$24,525,425
- Abdolmohamad Rostami · Thomas Jefferson University$23,969,638
- Stephen D Miller · Northwestern University$23,969,272
Research focus
Multiple SclerosisMediatingDemyelinationsGrantImmuneDisabilitySiteAxonPathologyPharmaceutical PreparationsMyelinNeuronsInflammationPathway InteractionsIn VivoClinical TrialsMagnetic Resonance ImagingBrainGray MatterImmunotherapyInflammatoryBrain TissueImageAtrophic
Grant awards (55)
Imaging Neurodegeneration in Multiple Sclerosis$626,596
R01 · FY2025 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$442,217
R01 · FY2025 · NS · contact PI
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis$1,217,659
U01 · FY2024 · NS · contact PI
Imaging Neurodegeneration in Multiple Sclerosis$662,494
R01 · FY2024 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$480,107
R01 · FY2024 · NS · contact PI
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis$1,262,170
U01 · FY2023 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$498,784
R01 · FY2023 · NS · contact PI
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis$1,270,249
U01 · FY2022 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$596,477
R01 · FY2022 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$505,265
R01 · FY2022 · NS · contact PI
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis$1,277,337
U01 · FY2021 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$592,478
R01 · FY2021 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$507,648
R01 · FY2021 · NS · contact PI
Validation of Serum Neurofilament Light Chain as a Prognostic and Monitoring Biomarker in Multiple Sclerosis$1,297,756
U01 · FY2020 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$585,102
R01 · FY2020 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$628,385
R01 · FY2019 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$450,313
R37 · FY2019 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$640,149
R01 · FY2018 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$450,313
R37 · FY2018 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$449,740
R37 · FY2017 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$354,375
R01 · FY2017 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$405,000
R37 · FY2016 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$354,375
R01 · FY2016 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$442,785
R01 · FY2015 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$405,000
R37 · FY2015 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$436,412
R01 · FY2014 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$400,950
R37 · FY2014 · NS · contact PI
Imaging neurodegeneration in multiple sclerosis$438,855
R01 · FY2013 · NS · contact PI
Mechanisms by which effector T cells modulate endogenous remyelination$405,000
R37 · FY2013 · NS · contact PI
Selective modulation of thyroid hormone receptors to promote remyelination$195,413
R21 · FY2013 · NS · contact PI
The Role of KV1.3 in Effector T cells$347,733
R01 · FY2012 · NS · contact PI
Selective modulation of thyroid hormone receptors to promote remyelination$243,000
R21 · FY2012 · NS · contact PI
The Role of KV1.3 in Effector T cells$347,816
R01 · FY2011 · NS · contact PI
MECHANISMS OF NEURODEGENERATION AND STRATEGIES FOR NEUROPROTECTION IN MS$37,455
P41 · FY2011 · RR · contact PI
The Role of KV1.3 in Effector T cells$351,545
R01 · FY2010 · NS · contact PI
MECHANISMS OF NEURODEGENERATION AND STRATEGIES FOR NEUROPROTECTION IN MS$31,771
P41 · FY2010 · RR · contact PI
The Role of KV1.3 in Effector T cells$355,175
R01 · FY2009 · NS · contact PI
MECHANISMS OF NEURODEGENERATION AND STRATEGIES FOR NEUROPROTECTION IN MS$32,050
P41 · FY2009 · RR · contact PI
The Role of KV1.3 in Effector T cells$371,384
R01 · FY2008 · NS · contact PI
MECHANISMS OF NEURODEGENERATION AND STRATEGIES FOR NEUROPROTECTION IN MS$22,050
P41 · FY2008 · RR · contact PI
MECHANISMS OF NEURODEGENERATION AND STRATEGIES FOR NEUROPROTECTION IN MS$34,526
P41 · FY2007 · RR · contact PI
ATORVASTATIN THERAPY IN EARLY MULTIPLE SCLEROSIS$262
M01 · FY2007 · RR · contact PI
ANALYSIS OF THE AXONAL DEGENERATION FOLLOWING INFLAMMATORY DEMYELINATION IN MULT$152
M01 · FY2007 · RR · contact PI
AVONEX COMBINATION TRIAL (ACT)$112
M01 · FY2007 · RR · contact PI
Potassium Channel Expression on Myelin Reactive Effector T Cells$265,431
R01 · FY2006 · NS · contact PI
AVONEX COMBINATION TRIAL (ACT)$2,192
M01 · FY2006 · RR · contact PI
ANALYSIS OF THE AXONAL DEGENERATION FOLLOWING INFLAMMATORY DEMYELINATION IN MULT$822
M01 · FY2006 · RR · contact PI
Potassium Channel Expression on Myelin Reactive Effector T Cells$271,819
R01 · FY2005 · NS
AVONEX COMBINATION TRIAL (ACT)$3,489
M01 · FY2005 · RR
PHASE II/III STUDY OF RITUXIMAB IN ADULTS WITH MS$748
M01 · FY2005 · RR
Potassium Channel Expression on Myelin Reactive Effector T Cells$271,819
R01 · FY2004 · NS
K+ Channel Expression on Myelin Reactive Effector T Cell$271,819
R01 · FY2003 · NS
CHEMOKINE RECEPTOR EXPRESSION ON MBP REACTIVE T CELLS$185,625
R01 · FY2002 · NS
CHEMOKINE RECEPTOR EXPRESSION ON MBP REACTIVE T CELLS$185,625
R01 · FY2001 · NS
CHEMOKINE RECEPTOR EXPRESSION ON MBP REACTIVE T CELLS$185,625
R01 · FY2000 · NS